Skip to main content

Table 2 Top 40 overrepresented Gene Ontology biological processes (FDR < 0.0001) in alternatively spliced genes in stage 4+ vs. 1- tumors

From: Exon array analysis reveals neuroblastoma tumors have distinct alternative splicing patterns according to stage and MYCN amplification status

GO Term

# Gene

PValue

cell cycle process **

203

2.26E-15

mitotic cell cycle **

107

8.64E-15

cellular component organization and biogenesis *

572

1.07E-14

cell cycle **

230

1.33E-14

cell cycle phase **

115

2.03E-14

mitosis **

84

2.29E-14

cell division **

88

3.86E-14

M phase of mitotic cell cycle **

84

4.03E-14

M phase **

97

1.28E-13

organelle organization and biogenesis *

285

1.67E-13

developmental process

651

4.37E-12

nervous system development *

192

1.66E-10

multicellular organismal development

479

4.24E-10

cellular process

2167

4.71E-10

chromosome segregation

32

7.47E-10

anatomical structure development

441

1.43E-9

localization

610

1.10E-8

regulation of cell cycle **

135

1.11E-8

cell cycle checkpoint

30

1.15E-8

cytoskeleton organization and biogenesis *

134

1.41E-8

system development

364

1.93E-8

regulation of progression through cell cycle **

133

2.61E-8

DNA replication **

74

7.81E-8

synaptic transmission *

84

2.63E-7

transmission of nerve pulse

93

2.98E-7

establishment of localization

533

5.36E-7

intracellular signaling cascade

307

6.77E-7

cell proliferation

179

7.05E-7

transport

516

7.30E-7

mitotic sister chromatid segregation

18

7.33E-7

response to DNA damage stimulus **

86

1.18E-6

sister chromatid segregation

18

1.33E-6

biological adhesion *

173

1.67E-6

cell adhesion *

173

1.67E-6

DNA metabolic process **

188

2.59E-6

cell communication

747

7.35E-6

interphase

34

1.15E-5

DNA replication initiation

16

2.45E-5

DNA-dependent DNA replication **

36

2.54E-5

cell differentiation

355

2.55E-5

  1. * GO terms that are also enriched in alternatively spliced genes in stage 4- vs 1- tumors.
  2. ** GO terms that are also enriched in differentially expressed genes in stage 4- vs 1- tumors.